Medibank Performance Rights Lapse Reduces Potential Equity Dilution

Medibank Private ( (AU:MPL) ) just unveiled an update.

Medibank Private has notified the market of the lapse of 118,539 performance rights, recorded as MPLAA securities on the ASX. The rights ceased on 31 March 2026 because the conditions attached to them were not satisfied or had become incapable of being met.

The cessation of these performance rights reduces Medibank’s potential equity dilution from this tranche of incentive securities. It also signals that specific performance or service hurdles linked to this award cycle were not achieved, which may be relevant for investors tracking executive and employee incentive outcomes and their alignment with shareholder returns.

The most recent analyst rating on (AU:MPL) stock is a Hold with a A$4.85 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.

More about Medibank Private

Medibank Private Limited is an Australian private health insurance company listed on the ASX under the code MPL. The group provides health insurance products and related services to individuals and corporate customers across Australia, operating as a major player in the national private healthcare funding market.

Average Trading Volume: 7,584,158

Technical Sentiment Signal: Buy

Current Market Cap: A$12.23B

For an in-depth examination of MPL stock, go to TipRanks’ Overview page.